Effect of quercetin on the plasma and intracellular concentrations of saquinavir in healthy adults

Pharmacotherapy

Volumn 26, Issue 9 I, 2006, Pages 1255-1261

  DiCenzo, Robert ^a,b   Frerichs, Valerie ^a   Larppanichpoonphol, Panupong ^b   Predko, Lisa ^b   Chen, Amy ^a   Reichman, Richard ^b   Morris, Marilyn ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Coadministration; Intracellular concentration; Pharmacokinetics; Plasma concentration; Quercetin; Saquinavir

Indexed keywords

ABC TRANSPORTER; ANTIPARASITIC AGENT; BIOFLAVONOID; CONTRACEPTIVE AGENT; CYCLOSPORIN; CYTOCHROME P450 1A1; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIGOXIN; GARLIC EXTRACT; GLYCOPROTEIN P; HERBACEOUS AGENT; HORMONE; HYPERICUM PERFORATUM EXTRACT; INTESTINE ENZYME; LIVER ENZYME; MESSENGER RNA; MOXIDECTIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NON PRESCRIPTION DRUG; PACLITAXEL; QUERCETIN; RHODAMINE 123; SAQUINAVIR; VERAPAMIL;

ABDOMINAL CRAMP; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DETERMINATION; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; INTRACELLULAR SPACE; MALE; NAUSEA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSPECTIVE STUDY; STEADY STATE; STOMACH DISEASE; TASTE DISORDER; UNIVERSITY;

ADULT; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; QUERCETIN; SAQUINAVIR;

EID: 33748096809     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.9.1255     Document Type: Article

References (30)

1. Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St John's wort. Lancet 2000;355:547-8.
2. Piscitelli SC, Burstein AH, Weiden N, Gallicano KD, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002;34:234-8.
3. Craig JC, Duncan IB, Hockley D, Grief C, Roberts NA, Mills JS. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antivir Res 1991;16:295-305.
4. Flexner C. Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits. Annu Rev Pharmacol Toxicol 2000;40:649-74.
5. Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 1997;25:256-66.
6. Gupta S, Gollapudi S. P-glycoprotein (MDR1 gene product) in cells of the immune system: its possible physiologic role and alteration in aging an human immunodeficiency virus-1 (HIV-1) infection. J Clin Immunol 1993;13:289-301.
7. Gollapudi S, Gupta S. Human immunodeficiency virus 1-induced expression of P-glycoprotein. Biochem Biophys Res Commun 1990;171:1002-7.
8. Diazani F, Antonelli G, Turriziani O, et al. Zidovudine increases the expression of cellular resistance affecting its antiviral activity. AIDS Res Hum Retroviruses 1994;10:1471-8.
9. Kim AE, Dintaman JM, Waddell DS, Silverman JA. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 1998;286:1439-45.
10. Sesink ALA, O'Leary KA, Hollman PCH. Quercetin glucuronides but not glucosides are present in human plasma after consumption of quercetin-3- glucoside or quercetin-4-glusoside. J Nutr 2001;131:1938-41.
11. Erlund I, Kosonen T, Alfthan G, et al. Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharm 2000;56:545-53.
12. Scambia G, Ranelletti FO, Panici PB, et al. Quercetin potentiates the effect of Adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 1994;34:459-64.
13. Hsiu SL, Hou YC, Wang YH, Tsao CW, Su SF, Chao PD. Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats. Life Sci 2002;72:227-35.
14. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000;294:88-95.
15. Frerichs VA, DiFrancesco R, Morse GD. Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry. J Chromatogr 2003;787:393-403.
16. Choi JS, Jo BW, Kim YC. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur J Pharm Biopharm 2004;57:313-18.
17. Wang YH, Chao PD, Hsiu SL, Wen KC, Hou YC. Lethal quercetin-digoxin interaction in pigs. Life Sci 2004;74:1191-7.
18. Dupuy J, Larrieu G, Sutra JF, Lespine A, Alvinerie M. Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: quercetin. Vet Parasitol 2003;112:337-47.
19. Eaglin VA, Profit L, Back DJ. Inhibition of CYP3A4-mediated and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol 1999;48:543-52.
20. Tsunoda SM, Harris RZ, Christians U, et al. Red wine decreases cyclosporine bioavailability. Clin Pharmacol Ther 2001;70:462-7.
21. Raucy JL. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 2003;31:533-9.
22. Wang L, Morris ME. Liquid chromatography-tandem mass spectroscopy assay for quercetin and conjugated quercetin metabolites in human plasma and urine. J Chromatogr B 2005;821:194-201.
23. Shapiro AB, Ling V. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 1997;250:130-7.
24. Shapiro AB, Fox K, Lam P, Ling V. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone: evidence for a third drug-binding site. Eur J Biochem 1999;259:841-50.
25. Williams GC, Liu A, Knipp G, Sinko PJ. Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother 2002;46:3456-62.
26. Hennessy M, Clarke S, Spiers JP, et al. Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokinetics. Antivir Ther 2002;8:191-8.
27. Hennessy M, Clarke S, Spiers JP, et al. Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients. Antivir Ther 2004;9:115-22.
28. SaKaeda T, Nakamura T, Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull 2002;25:1391-400.
29. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70:189-99.
30. Maeden ER, Hoggard PG, Newton P, et al. P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. J Antimicrob Chemother 2002;50:583-8.